GlassScriptPhysician profile
Hugh Don Cripps
NPI 1255323382
$4,849.25
in general payments reported to CMS, 2019-2025
39 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $521 · 2021: $396 · 2022: $792 · 2023: $860 · 2024: $645 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $892.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $412.48 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $341.36 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.71 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $307.00 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $306.63 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $262.24 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $244.10 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $212.07 | 2019-2023 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $177.57 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $162.78 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $116.92 | 2021-2024 | |
| Pfizer INC. | $100.18 | 2022-2025 | |
| Exact Sciences Corporation | $95.65 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.68 | 2025 | Caplyta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Cripps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.